OncoMed signs $2 billion anti-cancer deal with Bayer Schering Pharma
This article was originally published in Scrip
Executive Summary
OncoMed could receive more than $2 billion from Bayer Schering Pharma under a deal to develop and commercialise its anti-cancer stem cell therapeutics that target the Wnt signalling pathway.